Jameson Legal

 

Resource

 

 

 

 

 

 

 

 

 

 

 

Shearman & Sterling Advises Novartis on Its Proposed $3.9 Billion Acquisition of Advanced Accelerator Applications

07 Nov 2017

Shearman & Sterling is advising Novartis on its proposed $3.9 billion acquisition of Nasdaq-listed Advanced Accelerator Applications, a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines. The transaction will strengthen Novartis' oncology presence with both near-term product launches as well as a new technology platform with potential applications across a number of oncology early development programs.

Novartis provides innovative healthcare solutions and offers a diversified portfolio of innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis products are sold in approximately 155 countries around the world. The integration of Advanced Accelerator Applications with Novartis would build on Novartis' expertise in diseases associated with neuroendocrine tumors and introduce a new technology platform to Novartis providing an innovative approach to treating cancer.

The Shearman & Sterling team was led by partners George Casey and George Karafotias (both New York-Mergers & Acquisitions), Guillaume Isautier and Sami Toutounji (both Paris-Capital Markets), Doreen Lilienfeld (New York-Compensation, Governance & ERISA), Jordan Altman (New York-Mergers & Acquisitions), Niels Dejean (Paris-Tax) and Philip Urofsky (Washington DC-Litigation); counsel Barbara Le Chapellier (Paris-Mergers & Acquisitions), Ekaterina Zaboussova-Celsa (Paris-Compensation, Governance & ERISA), Anne-Sophie Maes (Paris-Tax) and Jason Pratt (New York-Environment); and associates Roger Morscheiser and Maroun El Hachem (both New York-Mergers & Acquisitions), Kim Doan (Paris-Mergers & Acquisitions), Kelly Hamren-Anderson (New York-Compensation, Governance & ERISA), David O’Steen (New York-Intellectual Property), Marc Elzweig (Menlo Park-Intellectual Property), Zahrah Devji and Joon Lee (both New York-Corporate).

The team also included partners Adam Hakki, Herve Letreguilly, Jeremy Kutner and Russell Sacks; Of Counsel Danforth Newcomb; counsel Francoise Even and Jonathan Handyside; and associates Andy Zwecker, Amandine Souin, Lev Gaft, Enrique Danacausa, Gavin Holmes, Gaspard Bastien-Thiry, Zana Operta, Bradley Simon, Jack Melamed, Leonardo Pinta, Fabbio Pazzini and Marie-Alexis Valente.

Matter Type
M&A: Acquiror's Counsel
Industry
Healthcare, Life Sciences & Chemicals
News Category
M&A